# Type I and Type III Interferons â€“ Induction, Signaling COVID-19

Cell Host and Microbe

27, 870-878

DOI: 10.1016/j.chom.2020.05.008

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19. Frontiers in Immunology, 2020, 11, 595739. | 2.2 | 90 |
| 2 | Syncytia formation by SARSâ€CoVâ€2â€infected cells. EMBO Journal, 2020, 39, e106267. | 3.5 | 361 |
| 3 | Severe COVID-19: what have we learned with the immunopathogenesis?. Advances in Rheumatology, 2020, 60, 50. | 0.8 | 53 |
| 4 | Evasion of Type I Interferon by SARS-CoV-2. Cell Reports, 2020, 33, 108234. | 2.9 | 742 |
| 5 | Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives. Frontiers in Microbiology, 2020, 11, 2016. | 1.5 | 11 |
| 6 | SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant. Cell Reports, 2020, 32, 108185. | 2.9 | 345 |
| 7 | Presentation, Treatment Response and Short-Term Outcomes in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). Journal of Clinical Medicine, 2020, 9, 3293. | 1.0 | 56 |
| 8 | Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection Response to SARS-CoV-2. Cell Stem Cell, 2020, 27, 905-919.e10. | 5.2 | 195 |
| 9 | An aberrant STAT pathway is central to COVID-19. Cell Death and Differentiation, 2020, 27, 3209-3225. | 5.0 | 224 |
| 10 | Association of immune checkpoint inhibitors with respiratory infections: A review. Cancer Treatment Reviews, 2020, 90, 102109. | 3.4 | 9 |
| 11 | Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. Immunity, 2020, 53, 487-495. | 6.6 | 127 |
| 12 | Infections of the lung: a predictive, preventive and personalized perspective through the lens of evolution, the emergence of SARS-CoV-2 and its pathogenesis. EPMA Journal, 2020, 11, 581-601. | 3.3 | 11 |
| 13 | Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?. Frontiers in Medicine, 2020, 7, 571597. | 1.2 | 10 |
| 14 | The Role of Structure in the Biology of Interferon Signaling. Frontiers in Immunology, 2020, 11, 606489. | 2.2 | 77 |
| 15 | Immunogenetic Association Underlying Severe COVID-19. Vaccines, 2020, 8, 700. | 2.1 | 30 |
| 16 | Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic. Frontiers in Pediatrics, 2020, 8, 605807. | 0.9 | 34 |
| 17 | COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. Frontiers in Microbiology, 2020, 11, 588409. | 1.5 | 19 |
| 18 | Context Is Key: Delineating the Unique Functions of IFNÎ± and IFNÎ² in Disease. Frontiers in Immunology, 2020, 11, 606874. | 2.2 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Cholesterol 25â€Hydroxylase inhibits <scp>SARS</scp> â€CoVâ€2 and other coronaviruses by depleting membrane cholesterol. EMBO Journal, 2020, 39, e106057. | 3.5 | 203 |
| 20 | Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. Frontiers in Oncology, 2020, 10, 572329. | 1.3 | 7 |
| 21 | Microglial responses to peripheral type 1 interferon. Journal of Neuroinflammation, 2020, 17, 340. | 3.1 | 35 |
| 22 | Approaches and Challenges in SARS-CoV-2 Vaccine Development. Cell Host and Microbe, 2020, 28, 364-370. | 5.1 | 98 |
| 23 | Molecular Underpinnings of Severe Coronavirus Disease 2019. JAMA - Journal of the American Medical Association, 2020, 324, 638. | 3.8 | 11 |
| 24 | Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochemical Pharmacology, 2020, 180, 114169. | 2.0 | 26 |
| 25 | Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. Cell Host and Microbe, 2020, 28, 455-464.e2. | 5.1 | 258 |
| 26 | Nonâ€steroidal antiâ€inflammatory drugs, prostaglandins, and COVIDâ€19. British Journal of Pharmacology, 2020, 177, 4899-4920. | 2.7 | 73 |
| 27 | A Message from the Human Placenta: Structural and Immunomodulatory Defense against SARS-CoV-2. Cells, 2020, 9, 1777. | 1.8 | 56 |
| 28 | A putative role for the tobacco mosaic virus in smokersâ€™ resistance to COVID-19. Medical Hypotheses, 2020, 143, 110153. | 0.8 | 12 |
| 29 | COVID-19 update: The race to therapeutic development. Drug Resistance Updates, 2020, 53, 100733. | 6.5 | 49 |
| 30 | Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 357 |
| 31 | SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans. MBio, 2020, 11, . | 1.8 | 106 |
| 32 | COVID-19: Infection or Autoimmunity. Frontiers in Immunology, 2020, 11, 2055. | 2.2 | 41 |
| 33 | Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. MBio, 2020, 11, . | 1.8 | 139 |
| 34 | Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. Viruses, 2020, 12, 1006. | 1.5 | 60 |
| 35 | Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets. Multiple Sclerosis and Related Disorders, 2020, 46, 102469. | 0.9 | 18 |
| 36 | In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age. PLoS Biology, 2020, 18, e3000849. | 2.6 | 225 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The current landscape of coronavirus-host proteinâ€“protein interactions. Journal of Translational Medicine, 2020, 18, 319. | 1.8 | 66 |
| 38 | SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nature Immunology, 2020, 21, 1327-1335. | 7.0 | 743 |
| 39 | Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Interferon and Cytokine Research, 2020, 40, 543-548. | 0.5 | 31 |
| 40 | Paediatric inflammatory multisystem syndrome temporally associated with COVID-19: a new virus and a new case presentation. BMJ Case Reports, 2020, 13, e238531. | 0.2 | 3 |
| 41 | Rationale for COVID-19 Treatment by Nebulized Interferon-Î²-1bâ€“Literature Review and Personal Preliminary Experience. Frontiers in Pharmacology, 2020, 11, 592543. | 1.6 | 11 |
| 42 | Enhancement of the IFN-Î²-induced host signature informs repurposed drugs for COVID-19. Heliyon, 2020, 6, e05646. | 1.4 | 18 |
| 43 | A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection. Frontiers in Immunology, 2020, 11, 590459. | 2.2 | 46 |
| 44 | Emerging Molecular Prospective of SARS-CoV-2: Feasible Nanotechnology Based Detection and Inhibition. Frontiers in Microbiology, 2020, 11, 2098. | 1.5 | 9 |
| 45 | Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology. Frontiers in Immunology, 2020, 11, 581076. | 2.2 | 6 |
| 46 | Integrate structural analysis, isoform diversity, and interferon-inductive propensity of ACE2 to predict SARS-CoV2 susceptibility in vertebrates. Heliyon, 2020, 6, e04818. | 1.4 | 13 |
| 47 | Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nature Reviews Immunology, 2020, 20, 453-454. | 10.6 | 284 |
| 49 | Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?. Cytokine and Growth Factor Reviews, 2020, 54, 43-50. | 3.2 | 19 |
| 50 | Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework. MBio, 2020, 11, . | 1.8 | 54 |
| 51 | Can BCG vaccine protect against COVIDâ€19 via trained immunity and tolerogenesis?. BioEssays, 2021, 43, e2000200. | 1.2 | 9 |
| 52 | Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology, 2021, 19, 141-154. | 13.6 | 3,334 |
| 53 | DockCoV2: a drug database against SARS-CoV-2. Nucleic Acids Research, 2021, 49, D1152-D1159. | 6.5 | 42 |
| 54 | Why COVID-19 is less frequent and severe in children: a narrative review. World Journal of Pediatrics, 2021, 17, 10-20. | 0.8 | 57 |
| 55 | Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nature Reviews Nephrology, 2021, 17, 46-64. | 4.1 | 444 |

| # | Article | IF | Citations |
|---|---|---|---|
| 56 | The role of kallikrein-kinin and renin-angiotensin systems in COVID-19 infection. Peptides, 2021, 135, 170428. | 1.2 | 19 |
| 57 | SARSâ€CoVâ€2â€mediated immune system activation and potential application in immunotherapy. Medicinal Research Reviews, 2021, 41, 1167-1194. | 5.0 | 37 |
| 58 | Interferon-inducer antivirals: Potential candidates to combat COVID-19. International Immunopharmacology, 2021, 91, 107245. | 1.7 | 32 |
| 59 | Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. International Immunopharmacology, 2021, 90, 107228. | 1.7 | 24 |
| 60 | A Prototype QSP Model of the Immune Response to SARSâ€CoVâ€2 for Community Development. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 18-29. | 1.3 | 16 |
| 61 | COVID19- clinical presentation and therapeutic considerations. Biochemical and Biophysical Research Communications, 2021, 538, 125-131. | 1.0 | 26 |
| 62 | The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. International Immunopharmacology, 2021, 90, 107225. | 1.7 | 75 |
| 63 | COVID-19: neonatalâ€“perinatal perspectives. Journal of Perinatology, 2021, 41, 940-951. | 0.9 | 62 |
| 64 | HEPN RNases â€“ an emerging class of functionally distinct RNA processing and degradation enzymes. Critical Reviews in Biochemistry and Molecular Biology, 2021, 56, 88-108. | 2.3 | 6 |
| 65 | Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nature Biotechnology, 2021, 39, 705-716. | 9.4 | 129 |
| 66 | Biomarkers for the clinical development of antiviral therapies. Cytometry Part B - Clinical Cytometry, 2021, 100, 19-32. | 0.7 | 2 |
| 67 | The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2. Environmental Toxicology and Pharmacology, 2021, 81, 103520. | 2.0 | 13 |
| 68 | SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response. Cellular and Molecular Immunology, 2021, 18, 613-620. | 4.8 | 143 |
| 69 | Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19. Phytomedicine, 2021, 85, 153315. | 2.3 | 100 |
| 70 | Tongue as a first-line immune organ?. Protein and Cell, 2021, 12, 162-164. | 4.8 | 4 |
| 71 | Influenza, but not SARSâ€CoVâ€2, infection induces a rapid interferon response that wanes with age and diminished tissueâ€resident memory CD8<sup>+</sup> T cells. Clinical and Translational Immunology, 2021, 10, e1242. | 1.7 | 25 |
| 73 | Macrophage Activation and Cytokine Release Syndrome in COVID-19: Current Updates and Analysis of Repurposed and Investigational Anti-Cytokine Drugs. Drug Research, 2021, 71, 173-179. | 0.7 | 8 |
| 74 | Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. Advances in Experimental Medicine and Biology, 2021, 1322, 219-260. | 0.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 75 | A distinct innate immune signature marks progression from mild to severe COVID-19. Cell Reports Medicine, 2021, 2, 100166. | 3.3 | 102 |
| 76 | Extreme phenotypes approach to investigate host genetics and COVID-19 outcomes. Genetics and Molecular Biology, 2021, 44, e20200302. | 0.6 | 6 |
| 77 | Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100048. | 1.7 | 6 |
| 78 | Rapidly Deployable Mouse Models of SARS-CoV-2 Infection Add Flexibility to the COVID-19 Toolbox. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 7-9. | 1.4 | 3 |
| 80 | Comparison of Five Serological Assays for the Detection of SARS-CoV-2 Antibodies. Diagnostics, 2021, 11, 78. | 1.3 | 14 |
| 81 | Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases. Annual Review of Microbiology, 2021, 75, 19-47. | 2.9 | 52 |
| 83 | Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185. | | 1 |
| 84 | A Novel Pathway Network Analytics Method Based on Graph Theory. Lecture Notes in Computer Science, 2021, , 45-55. | 1.0 | 0 |
| 85 | The Immune Response and Effectiveness of COVID-19 Therapies. Advances in Experimental Medicine and Biology, 2021, 1321, 115-126. | 0.8 | 6 |
| 86 | Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358. | 0.4 | 3 |
| 87 | Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19. Heliyon, 2021, 7, e05951. | 1.4 | 15 |
| 88 | Roles of Type I and III Interferons in COVID-19. Yonsei Medical Journal, 2021, 62, 381. | 0.9 | 17 |
| 89 | Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors. Cellular and Molecular Immunology, 2021, 18, 539-555. | 4.8 | 179 |
| 90 | Protective Immune Trajectories in Early Viral Containment of Non-Pneumonic SARS-CoV-2 Infection. SSRN Electronic Journal, 0, , . | 0.4 | 3 |
| 91 | Smoking Products Suppress Type I IFN During SARS-Cov-2 Infection. E3S Web of Conferences, 2021, 292, 03095. | 0.2 | 0 |
| 94 | Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARSâ€CoVâ€2 Spike Protein**. Angewandte Chemie - International Edition, 2021, 60, 7098-7110. | 7.2 | 77 |
| 95 | Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19. Emergent Materials, 2021, 4, 75-99. | 3.2 | 81 |
| 96 | The COVID-19 Pandemic: an Appraisal of its Impact on Human Immunodeficiency Virus Infection and Pre-Eclampsia. Current Hypertension Reports, 2021, 23, 9. | 1.5 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 97 | Ageâ€related differences in the immune response could contribute to determine the spectrum of severity of COVIDâ€19. Immunity, Inflammation and Disease, 2021, 9, 331-339. | 1.3 | 54 |
| 98 | Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 829-838. | 1.4 | 37 |
| 99 | Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARSâ€CoVâ€2 Spike Protein**. Angewandte Chemie, 2021, 133, 7174-7186. | 1.6 | 6 |
| 100 | COVID-19 and immunity: quo vadis?. International Immunology, 2021, 33, 507-513. | 1.8 | 5 |
| 103 | Cardiac manifestations, treatment characteristics, and outcomes of paediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2: A systematic review. Progress in Pediatric Cardiology, 2021, 63, 101365. | 0.2 | 8 |
| 104 | SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO. Cell Reports, 2021, 34, 108761. | 2.9 | 174 |
| 105 | SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cellular and Molecular Immunology, 2021, 18, 945-953. | 4.8 | 97 |
| 106 | Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology. Current Drug Targets, 2021, 22, 254-281. | 1.0 | 27 |
| 110 | Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions. International Journal of Molecular Sciences, 2021, 22, 2108. | 1.8 | 70 |
| 113 | Early humoral defence: Contributing to confining COVIDâ€19 to conducting airways?. Scandinavian Journal of Immunology, 2021, 93, e13024. | 1.3 | 10 |
| 115 | The intersection of COVID-19 and autoimmunity: What is our current understanding?. Pathogens and Immunity, 2021, 6, 31-54. | 1.4 | 20 |
| 117 | Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense. Bosnian Journal of Basic Medical Sciences, 2021, 21, 515-527. | 0.6 | 4 |
| 118 | SARS-CoV-2 Triggers an MDA-5-Dependent Interferon Response Which Is Unable To Control Replication in Lung Epithelial Cells. Journal of Virology, 2021, 95, . | 1.5 | 168 |
| 119 | Endogenous IFNÎ² expression predicts outcome in critical patients with COVID-19. Lancet Microbe, The, 2021, 2, e235-e236. | 3.4 | 7 |
| 120 | Ribosome-Profiling Reveals Restricted Post Transcriptional Expression of Antiviral Cytokines and Transcription Factors during SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2021, 22, 3392. | 1.8 | 22 |
| 121 | A novel cell culture system modeling the SARS-CoV-2 life cycle. PLoS Pathogens, 2021, 17, e1009439. | 2.1 | 102 |
| 122 | Extrapulmonary manifestations of COVID-19 in children: a comprehensive review and pathophysiological considerations. Jornal De Pediatria, 2021, 97, 116-139. | 0.9 | 46 |
| 123 | Modern opportunities of interferons in treatment of children with COVID-19. Meditsinskiy Sovet, 2021, , 59-65. | 0.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 124 | High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients. Cellular and Molecular Life Sciences, 2021, 78, 3987-4002. | 2.4 | 13 |
| 126 | Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus. Reviews in Medical Virology, 2021, 31, e2234. | 3.9 | 12 |
| 128 | Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice. Fundamental Research, 2021, 1, 124-130. | 1.6 | 5 |
| 129 | Risk of SARS-CoV-2 reinfection after natural infection. Lancet, The, 2021, 397, 1161-1163. | 6.3 | 53 |
| 130 | IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection. Communications Biology, 2021, 4, 290. | 2.0 | 74 |
| 131 | Association of administration of IFN-Î± with mortality among patients hospitalized with coronavirus disease 2019. Future Virology, 2021, 16, 201-209. | 0.9 | 1 |
| 133 | Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nature Communications, 2021, 12, 1967. | 5.8 | 107 |
| 134 | SARS-CoV-2 - SYNOPTIC CHART OF THE MAIN CHARACTERISTICS OF VIRUS, PATHOGENESIS, IMMUNE RESPONSE, IMMUNOPROPHYLAXIS. Roumanian Archives of Microbiology and Immunology, 2021, 80, 51-80. | 0.1 | 1 |
| 135 | Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-Î³ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome. Frontiers in Immunology, 2021, 12, 654587. | 2.2 | 39 |
| 136 | Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2. Frontiers in Immunology, 2021, 12, 655528. | 2.2 | 19 |
| 137 | Clinical Characteristics of Paediatric Hyperinflammatory Syndrome in the Era of Corona Virus Disease 2019 (COVID-19). Indian Journal of Clinical Biochemistry, 2021, 36, 404-415. | 0.9 | 4 |
| 138 | A 2-Benzylmalonate Derivative as STAT3 Inhibitor Suppresses Tumor Growth in Hepatocellular Carcinoma by Upregulating Î²-TrCP E3 Ubiquitin Ligase. International Journal of Molecular Sciences, 2021, 22, 3354. | 1.8 | 4 |
| 142 | Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. Journal of Allergy and Clinical Immunology, 2021, 147, 857-869.e7. | 1.5 | 45 |
| 143 | Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity, 2021, 54, 557-570.e5. | 6.6 | 153 |
| 146 | Reply to Dorgham et al., â€œConsidering Personalized Interferon Beta Therapy for COVID-19â€• Antimicrobial Agents and Chemotherapy, 2021, 65, . | 1.4 | 0 |
| 148 | COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. Infectious Disease Reports, 2021, 13, 259-284. | 1.5 | 27 |
| 149 | Natural mucosal barriers and COVID-19 in children. JCI Insight, 2021, 6, . | 2.3 | 124 |
| 150 | SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia. Frontiers in Immunology, 2021, 12, 656700. | 2.2 | 49 |

| # | Article | IF | Citations |
|---|---|---|---|
| 151 | IFN Stimulates ACE2 Expression in Pediatric Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 515-518. | 1.4 | 11 |
| 152 | Singleâ€cell analyses reveal SARSâ€CoVâ€2 interference with intrinsic immune response in the human gut. Molecular Systems Biology, 2021, 17, e10232. | 3.2 | 78 |
| 153 | Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. ACS Central Science, 2021, 7, 792-802. | 5.3 | 59 |
| 154 | Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. Cytokine and Growth Factor Reviews, 2021, 58, 55-65. | 3.2 | 11 |
| 155 | Type I Interferon Production of Plasmacytoid Dendritic Cells under Control. International Journal of Molecular Sciences, 2021, 22, 4190. | 1.8 | 40 |
| 156 | SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis. Life Sciences, 2021, 270, 119124. | 2.0 | 57 |
| 158 | Ã‡ocuklarda Covid 19 Ä°liÅŸkili Multisistem Ä°nflamatuar Sendrom Patofizyolojisi. SÃ¼leyman Demirel Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , . | 0.0 | 0 |
| 159 | The use of intranasal interferon for prevention and treatment of acute respiratory infections. AktualÊ¹naÃ¢ InfektologiÃ¢, 2021, 9, 17-23. | 0.1 | 0 |
| 162 | Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. Trends in Immunology, 2021, 42, 312-322. | 2.9 | 86 |
| 163 | Differential Signaling and Virus Production in Calu-3 Cells and Vero Cells upon SARS-CoV-2 Infection. Biomolecules and Therapeutics, 2021, 29, 273-281. | 1.1 | 36 |
| 164 | Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. IScience, 2021, 24, 102477. | 1.9 | 49 |
| 165 | Type I and III interferon responses in SARS-CoV-2 infection. Experimental and Molecular Medicine, 2021, 53, 750-760. | 3.2 | 187 |
| 166 | Low incidence of COVID-19 severe complications in a large cohort of children with sickle cell disease: a protective role for basal interferon-1 activation?. Haematologica, 2021, 106, 2746-2748. | 1.7 | 6 |
| 167 | Pharmacological activation of STING blocks SARS-CoV-2 infection. Science Immunology, 2021, 6, . | 5.6 | 123 |
| 168 | Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. Science Translational Medicine, 2021, 13, . | 5.8 | 50 |
| 169 | Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respiratory Medicine,the, 2021, 9, 498-510. | 5.2 | 180 |
| 170 | A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection. Science Immunology, 2021, 6, . | 5.6 | 96 |
| 171 | Immunological Subpopulations Within Critically Ill COVID-19 Patients. Chest, 2021, 159, 1706-1708. | 0.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 172 | Diagnosing SARS-CoV-2 with Antigen Testing, Transcription-Mediated Amplification and Real-Time PCR. Journal of Clinical Medicine, 2021, 10, 2404. | 1.0 | 19 |
| 173 | Promising Immunotherapies against COVIDâ€19. Advanced Therapeutics, 2021, 4, 2100044. | 1.6 | 4 |
| 175 | SARSâ€CoVâ€2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIGâ€I/MDAâ€5â€“MAVS, TLR3â€“TRIF, and cGASâ€“STING signaling pathways. Journal of Medical Virology, 2021, 93, 5376-5389. | 2.5 | 153 |
| 177 | Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV,the, 2021, 8, e294-e305. | 2.1 | 129 |
| 178 | Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 657363. | 2.2 | 34 |
| 179 | Innate immune sensing of coronavirus and viral evasion strategies. Experimental and Molecular Medicine, 2021, 53, 723-736. | 3.2 | 130 |
| 180 | Multisystem inflammatory syndrome in children during the coronavirus disease pandemic of 2019: a review of clinical features and acute phase management. Journal of Anesthesia, 2021, 35, 563-570. | 0.7 | 5 |
| 181 | Interferon Inducer IFI35 Regulates RIG-I-Mediated Innate Antiviral Response through Mutual Antagonism with Influenza Virus Protein NS1. Journal of Virology, 2021, 95, . | 1.5 | 15 |
| 182 | Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses. Frontiers in Immunology, 2021, 12, 656433. | 2.2 | 11 |
| 183 | Histomorphological patterns of regional lymph nodes in COVID-19 lungs. Der Pathologe, 2021, 42, 89-97. | 0.7 | 19 |
| 184 | Adipocyte inflammation and pathogenesis of viral pneumonias: an overlooked contribution. Mucosal Immunology, 2021, 14, 1224-1234. | 2.7 | 16 |
| 186 | Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity. Journal of Infectious Diseases, 2021, 224, 777-782. | 1.9 | 26 |
| 188 | Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections. Frontiers in Immunology, 2021, 12, 660298. | 2.2 | 8 |
| 189 | Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. Pediatric Rheumatology, 2021, 19, 68. | 0.9 | 7 |
| 190 | Therapeutic Targeting of Transcription Factors to Control the Cytokine Release Syndrome in COVID-19. Frontiers in Pharmacology, 2021, 12, 673485. | 1.6 | 10 |
| 191 | Human Defensins Inhibit SARS-CoV-2 Infection by Blocking Viral Entry. Viruses, 2021, 13, 1246. | 1.5 | 35 |
| 192 | Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators. International Journal of Molecular Sciences, 2021, 22, 7017. | 1.8 | 43 |
| 193 | Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update. Frontiers in Immunology, 2021, 12, 658519. | 2.2 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 195 | A combination treatment of IFN-Î±2b and IFN-Î³ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trial. Annals of Antivirals and Antiretrovirals, 2021, , 001-014. | 0.5 | 2 |
| 196 | Cellular nucleic acidâ€“binding protein is essential for type I interferonâ€“mediated immunity to RNA virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 10 |
| 197 | Activation of cGAS/STING pathway upon paramyxovirus infection. IScience, 2021, 24, 102519. | 1.9 | 25 |
| 198 | The Role of Coronavirus RNA-Processing Enzymes in Innate Immune Evasion. Life, 2021, 11, 571. | 1.1 | 12 |
| 199 | Multisystem Inflammatory Syndrome in Children Associated with COVID-19: An Interim Review. Journal of Pediatric Infectious Diseases, 0, 16, . | 0.1 | 0 |
| 200 | Severe COVID-19 Recovery Is Associated with Timely Acquisition of a Myeloid Cell Immune-Regulatory Phenotype. Frontiers in Immunology, 2021, 12, 691725. | 2.2 | 36 |
| 202 | Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clinical Microbiology Reviews, 2021, 34, . | 5.7 | 141 |
| 203 | Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy. Journal of Medicinal Chemistry, 2022, 65, 955-982. | 2.9 | 48 |
| 205 | A Hepatitis B Virus-Derived Peptide Can Inhibit Infection of Human Lung Cells with SARS-CoV-2 in a Type-1 Interferon-Dependent Manner. Viruses, 2021, 13, 1227. | 1.5 | 3 |
| 206 | SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. Immunity, 2021, 54, 1304-1319.e9. | 6.6 | 115 |
| 207 | Efficacy of CytoSorb in a Pediatric Case of Severe Multisystem Infammatory Syndrome (MIS-C): A Clinical Case Report. Frontiers in Pediatrics, 2021, 9, 676298. | 0.9 | 10 |
| 208 | COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?. Translational Research, 2021, 232, 1-12. | 2.2 | 45 |
| 210 | An Impaired Inflammatory and Innate Immune Response in COVID-19. Molecules and Cells, 2021, 44, 384-391. | 1.0 | 13 |
| 212 | Rapid, reliable, and reproducible cell fusion assay to quantify SARS-Cov-2 spike interaction with hACE2. PLoS Pathogens, 2021, 17, e1009683. | 2.1 | 18 |
| 213 | SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors. Journal of Virology, 2021, 95, e0026621. | 1.5 | 72 |
| 215 | SARS-CoV-2 Antiviral Therapy. Clinical Microbiology Reviews, 2021, 34, e0010921. | 5.7 | 64 |
| 216 | High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings. PLoS ONE, 2021, 16, e0254129. | 1.1 | 30 |
| 217 | SARSâ€CoVâ€2 sensing by RIGâ€I and MDA5 links epithelial infection to macrophage inflammation. EMBO Journal, 2021, 40, e107826. | 3.5 | 144 |

| # | Article | IF | Citations |
|---|---|---|---|
| 218 | Supramolecular Cylinders Target Bulge Structures in the 5â€² UTR of the RNA Genome of SARSâ€CoVâ€2 and Inhibit Viral Replication**. Angewandte Chemie - International Edition, 2021, 60, 18144-18151. | 7.2 | 12 |
| 219 | ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions. PLoS Pathogens, 2021, 17, e1009723. | 2.1 | 28 |
| 220 | COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases. International Journal of Molecular Sciences, 2021, 22, 7481. | 1.8 | 37 |
| 221 | The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN-Î³ production in vitro. International Immunopharmacology, 2021, 96, 107797. | 1.7 | 13 |
| 222 | Innate Immunity in Children and the Role of ACE2 Expression in SARS-CoV-2 Infection. Pediatric Reports, 2021, 13, 363-382. | 0.5 | 18 |
| 223 | Supramolecular Cylinders Target Bulge Structures in the 5â€² UTR of the RNA Genome of SARSâ€CoVâ€2 and Inhibit Viral Replication**. Angewandte Chemie, 2021, 133, 18292-18299. | 1.6 | 3 |
| 225 | Immunity and Viral Infections: Modulating Antiviral Response via CRISPRâ€“Cas Systems. Viruses, 2021, 13, 1373. | 1.5 | 9 |
| 226 | COVID-19 virtual patient cohort suggests immune mechanisms driving disease outcomes. PLoS Pathogens, 2021, 17, e1009753. | 2.1 | 61 |
| 227 | The Many Faces of JAKs and STATs Within the COVID-19 Storm. Frontiers in Immunology, 2021, 12, 690477. | 2.2 | 18 |
| 228 | The RNA sensor MDA5 detects SARS-CoV-2 infection. Scientific Reports, 2021, 11, 13638. | 1.6 | 93 |
| 230 | Commentary: Why Havenâ€™t We Found an Effective Treatment for COVID-19?. Frontiers in Immunology, 2021, 12, 714175. | 2.2 | 2 |
| 231 | SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance. Nature Communications, 2021, 12, 4354. | 5.8 | 154 |
| 232 | Host factors facilitating SARSâ€CoVâ€2 virus infection and replication in the lungs. Cellular and Molecular Life Sciences, 2021, 78, 5953-5976. | 2.4 | 19 |
| 233 | Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature Reviews Immunology, 2021, 21, 475-484. | 10.6 | 434 |
| 234 | Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. Cell Reports, 2021, 36, 109364. | 2.9 | 109 |
| 235 | The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduction and Targeted Therapy, 2021, 6, 255. | 7.1 | 355 |
| 238 | Insights into the modulation of the interferon response and NAD+ in the context of COVID-19. International Reviews of Immunology, 2021, , 1-11. | 1.5 | 7 |
| 240 | The early interferon catches the SARS-CoV-2. Journal of Experimental Medicine, 2021, 218, . | 4.2 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 241 | Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. Journal of Experimental Medicine, 2021, 218, . | 4.2 | 85 |
| 242 | COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine and Growth Factor Reviews, 2021, 60, 28-45. | 3.2 | 21 |
| 243 | Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. PLoS Pathogens, 2021, 17, e1009427. | 2.1 | 38 |
| 244 | Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients. Journal of Microbiology, Immunology and Infection, 2022, 55, 421-427. | 1.5 | 15 |
| 245 | Hypothesis: Neuroglia Activation Due to Increased Peripheral and CNS Proinflammatory Cytokines/Chemokines with Neuroinflammation May Result in Long COVID. Neuroglia (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 577 | 0.8 | 14 |
| 247 | AHR signaling is induced by infection with coronaviruses. Nature Communications, 2021, 12, 5148. | 5.8 | 38 |
| 249 | Humoral and Cell-Mediated Immune Response in Colostrum from Women Diagnosed Positive for SARS-CoV-2. Breastfeeding Medicine, 2021, 16, 987-994. | 0.8 | 16 |
| 250 | Immunosuppression in Glomerular Diseases: Implications for SARS-CoV-2 Vaccines and COVID-19. Glomerular Diseases, 2021, 1, 277-293. | 0.2 | 4 |
| 251 | Quantitative circular flow immunoassays with trained object recognition to detect antibodies to SARS-CoV-2 membrane glycoprotein. Biochemical and Biophysical Research Communications, 2021, 565, 8-13. | 1.0 | 3 |
| 252 | COVID-19, corticosteroids and public health: a reappraisal. Public Health, 2021, 197, 48-55. | 1.4 | 7 |
| 253 | Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nature Biotechnology, 2022, 40, 319-324. | 9.4 | 229 |
| 255 | Decoding the dynamics of multilayered stochastic antiviral IFN-I responses. Trends in Immunology, 2021, 42, 824-839. | 2.9 | 29 |
| 256 | SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response. MBio, 2021, 12, e0233521. | 1.8 | 57 |
| 257 | The Suppressor of Cytokine Signalling family of proteins and their potential impact on COVIDâ€19 disease progression. Reviews in Medical Virology, 2022, 32, e2300. | 3.9 | 11 |
| 259 | Inhibition of SARS-CoV-2 Infection by Human Defensin HNP1 and Retrocyclin RC-101. Journal of Molecular Biology, 2022, 434, 167225. | 2.0 | 19 |
| 260 | A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine. Frontiers in Immunology, 2021, 12, 729189. | 2.2 | 23 |
| 261 | The role of type I interferon in the treatment of COVIDâ€19. Journal of Medical Virology, 2022, 94, 63-81. | 2.5 | 52 |
| 262 | Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy. Dermatology and Therapy, 2021, 11, 1889-1903. | 1.4 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 263 | Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Science Immunology, 2021, 6, eabl4509. | 5.6 | 141 |
| 264 | High Prevalence of Pre-Existing Liver Abnormalities Identified Via Autopsies in COVID-19: Identification of a New Silent Risk Factor?. Diagnostics, 2021, 11, 1703. | 1.3 | 3 |
| 265 | The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell, 2021, 184, 4953-4968.e16. | 13.5 | 165 |
| 266 | Interferon Î², an enhancer of the innate immune response against SARS-CoV-2 infection. Microbial Pathogenesis, 2021, 158, 105105. | 1.3 | 6 |
| 268 | Mechanisms of Antiviral Immune Evasion of SARS-CoV-2. Journal of Molecular Biology, 2022, 434, 167265. | 2.0 | 72 |
| 269 | On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers. Frontiers in Immunology, 2021, 12, 705646. | 2.2 | 9 |
| 270 | The immune response to SARS-CoV-2 and COVID-19 immunopathology â€“ Current perspectives. Pulmonology, 2021, 27, 423-437. | 1.0 | 118 |
| 271 | Forms and Methods for Interferonâ€™s Encapsulation. Pharmaceutics, 2021, 13, 1533. | 2.0 | 9 |
| 272 | Pediatric COVID-19: Immunopathogenesis, Transmission and Prevention. Vaccines, 2021, 9, 1002. | 2.1 | 16 |
| 273 | Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease. PLoS Pathogens, 2021, 17, e1009850. | 2.1 | 22 |
| 274 | COVID19db: a comprehensive database platform to discover potential drugs and targets of COVID-19 at whole transcriptomic scale. Nucleic Acids Research, 2022, 50, D747-D757. | 6.5 | 27 |
| 275 | A hitchhiker's guide through the COVID-19 galaxy. Clinical Immunology, 2021, 232, 108849. | 1.4 | 3 |
| 276 | SARS-CoV-2 Spike protein enhances ACE2 expression via facilitating Interferon effects in bronchial epithelium. Immunology Letters, 2021, 237, 33-41. | 1.1 | 19 |
| 277 | The MAVS Immune Recognition Pathway in Viral Infection and Sepsis. Antioxidants and Redox Signaling, 2021, 35, 1376-1392. | 2.5 | 24 |
| 278 | Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection. PLoS Pathogens, 2021, 17, e1009878. | 2.1 | 52 |
| 279 | Host proviral and antiviral factors for SARS-CoV-2. Virus Genes, 2021, 57, 475-488. | 0.7 | 11 |
| 280 | Prompt Reduction in CRP, IL-6, IFN-Î³, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19. Frontiers in Medicine, 2021, 8, 734838. | 1.2 | 13 |
| 281 | Clinical Patterns and Morphology of COVID-19 Dermatology. Dermatologic Clinics, 2021, 39, 487-503. | 1.0 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 282 | Immunomodulation and immunotherapeutics of COVID-19. Clinical Immunology, 2021, 231, 108842. | 1.4 | 7 |
| 283 | HantavirusesDB: Vaccinomics and RNA-based therapeutics database for the potentially emerging human respiratory pandemic agents. Microbial Pathogenesis, 2021, 160, 105161. | 1.3 | 4 |
| 284 | Gut probiotic Lactobacillus rhamnosus attenuates PDE4B-mediated interleukin-6 induced by SARS-CoV-2 membrane glycoprotein. Journal of Nutritional Biochemistry, 2021, 98, 108821. | 1.9 | 13 |
| 285 | The Abstruse Side of Type I Interferon Immunotherapy for COVID-19 Cases with Comorbidities. Journal of Respiration, 2021, 1, 49-59. | 0.4 | 5 |
| 286 | Novel coronavirus disease (COVID-19) pandemic: A recent mini review. Computational and Structural Biotechnology Journal, 2021, 19, 612-623. | 1.9 | 35 |
| 287 | Immune evasion of SARS-CoV-2 from interferon antiviral system. Computational and Structural Biotechnology Journal, 2021, 19, 4217-4225. | 1.9 | 49 |
| 288 | Mechanisms of infection by SARS-CoV-2, inflammation and potential links with the microbiome. Future Virology, 2021, 16, 43-57. | 0.9 | 10 |
| 289 | Proteomic Signature of Host Response to SARS-CoV-2 Infection in the Nasopharynx. Molecular and Cellular Proteomics, 2021, 20, 100134. | 2.5 | 25 |
| 290 | COVID-19: disease, or no disease? - that is the question. Itâ€™s the dose stupid!. Microbes and Infection, 2021, 23, 104779. | 1.0 | 7 |
| 292 | The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 100 |
| 293 | Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain. Pain Reports, 2021, 6, e885. | 1.4 | 83 |
| 294 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Signal Transduction and Targeted Therapy, 2020, 5, 299. | 7.1 | 232 |
| 295 | Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission. Clinical Science, 2020, 134, 2137-2160. | 1.8 | 68 |
| 296 | SARS-CoV-2 reinfection and implications for vaccine development. Human Vaccines and Immunotherapeutics, 2020, 16, 3061-3073. | 1.4 | 54 |
| 297 | Innate immunology in COVID-19â€”a living review. Part I: viral entry, sensing and evasion. Oxford Open Immunology, 2020, 1, iqaa004. | 1.2 | 7 |
| 298 | The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2. Current Opinion in HIV and AIDS, 2021, 16, 36-47. | 1.5 | 6 |
| 327 | Is innate immunity our best weapon for flattening the curve?. Journal of Clinical Investigation, 2020, 130, 3954-3956. | 3.9 | 11 |
| 328 | SARS-CoV-2 meta-interactome suggests disease-specific, autoimmune pathophysiologies and therapeutic targets. F1000Research, 2020, 9, 992. | 0.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 329 | Cardiovascular impact of COVID-19 with a focus on children: A systematic review. World Journal of Clinical Cases, 2020, 8, 5250-5283. | 0.3 | 78 |
| 330 | Evaluation of the automated cartridge-based ARIES SARS-CoV-2 Assay (RUO) against automated Cepheid Xpert Xpress SARS-CoV-2 PCR as gold standard. European Journal of Microbiology and Immunology, 2020, 10, 156-164. | 1.5 | 12 |
| 331 | Evaluation of the Xiamen AmonMed Biotechnology rapid diagnostic test COVID-19 IgM/IgG test kit (Colloidal gold). European Journal of Microbiology and Immunology, 2020, 10, 178-185. | 1.5 | 5 |
| 332 | Mouse Model of SARS-CoV-2 Reveals Inflammatory Role of Type I Interferon Signaling. SSRN Electronic Journal, 2020, , 3628297. | 0.4 | 3 |
| 333 | Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques. Zoological Research, 2020, 41, 503-516. | 0.9 | 60 |
| 334 | Prospects for Using the ELISPOT Technological Platform as Part of Anti-Epidemic Measures Against the New Coronavirus Infection COVID-19. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 146-158. | 0.2 | 8 |
| 335 | COVIDâ€'19 in China: From epidemiology to treatment (Review). Experimental and Therapeutic Medicine, 2020, 20, 1-1. | 0.8 | 4 |
| 336 | Interferon therapy for COVID-19 and emerging infections: Prospects and concerns. Cleveland Clinic Journal of Medicine, 2020, , . | 0.6 | 22 |
| 337 | ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. ELife, 2020, 9, . | 2.8 | 266 |
| 338 | Topics of thrombosis with COVID-19â€"from a viewpoint of infectious disease specialistâ€". Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 628-631. | 0.1 | 0 |
| 339 | When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak. Frontiers in Immunology, 2021, 12, 692598. | 2.2 | 7 |
| 340 | ADAR Editing in Viruses: An Evolutionary Force to Reckon with. Genome Biology and Evolution, 2021, 13, . | 1.1 | 23 |
| 341 | Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. Nano Research, 2022, 15, 2196-2225. | 5.8 | 8 |
| 342 | Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166294. | 1.8 | 28 |
| 343 | Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. Science Immunology, 2021, 6, eabm3131. | 5.6 | 37 |
| 345 | Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures. European Respiratory Journal, 2022, 59, 2101881. | 3.1 | 37 |
| 346 | Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. Frontiers in Immunology, 2021, 12, 746203. | 2.2 | 10 |
| 347 | Microvascular Skin Manifestations Caused by COVID-19. Hamostaseologie, 2021, 41, 387-396. | 0.9 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 348 | Sterols, Oxysterols, and Accessible Cholesterol: Signalling for Homeostasis, in Immunity and During Development. Frontiers in Physiology, 2021, 12, 723224. | 1.3 | 11 |
| 349 | Lessons in self-defence: inhibition of virus entry by intrinsic immunity. Nature Reviews Immunology, 2022, 22, 339-352. | 10.6 | 66 |
| 351 | Cancer and Covid-19: Collectively catastrophic. Cytokine and Growth Factor Reviews, 2022, 63, 78-89. | 3.2 | 10 |
| 352 | COVID19 Disease Map, a computational knowledge repository of virusâ€“host interaction mechanisms. Molecular Systems Biology, 2021, 17, e10387. | 3.2 | 53 |
| 354 | Traditional Chinese Medicine, Qingfei Paidu Decoction and Xuanfei Baidu Decoction, Inhibited Cytokine Production via NF-ÎºB Signaling Pathway in Macrophages: Implications for Coronavirus Disease 2019 (COVID-19) Therapy. Frontiers in Pharmacology, 2021, 12, 722126. | 1.6 | 14 |
| 358 | Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Cells, 2021, 10, 2949. | 1.8 | 26 |
| 359 | Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2. Angiogenesis, 2022, 25, 225-240. | 3.7 | 27 |
| 363 | Myeloid dysregulation and therapeutic intervention in COVID-19. Seminars in Immunology, 2021, 55, 101524. | 2.7 | 9 |
| 364 | Interferons in Pain and Infections: Emerging Roles in Neuro-Immune and Neuro-Glial Interactions. Frontiers in Immunology, 2021, 12, 783725. | 2.2 | 36 |
| 365 | Hemin as a novel candidate for treating COVID-19 via heme oxygenase-1 induction. Scientific Reports, 2021, 11, 21462. | 1.6 | 20 |
| 367 | Covid-19: features of the pathogenesis of the disease and targets for immunotherapeutic effects. Meditsinskii Akademicheskii Zhurnal, 2020, 20, 75-88. | 0.2 | 0 |
| 368 | Devil's tools: SARS-CoV-2 antagonists against innate immunity. Current Research in Virological Science, 2021, 2, 100013. | 1.8 | 19 |
| 369 | Atypical Prolonged Viral Shedding With Intra-Host SARS-CoV-2 Evolution in a Mildly Affected Symptomatic Patient. Frontiers in Medicine, 2021, 8, 760170. | 1.2 | 16 |
| 370 | A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions. MBio, 2021, , e0293621. | 1.8 | 1 |
| 371 | SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Nature Communications, 2021, 12, 6602. | 5.8 | 104 |
| 372 | Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nature Medicine, 2022, 28, 201-211. | 15.2 | 132 |
| 373 | Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells. Frontiers in Pharmacology, 2021, 12, 765951. | 1.6 | 5 |
| 374 | A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. Journal of Experimental Medicine, 2022, 219, . | 4.2 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 375 | Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines. Current HIV/AIDS Reports, 2022, 19, 5-16. | 1.1 | 9 |
| 376 | An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants. Viruses, 2021, 13, 2302. | 1.5 | 32 |
| 377 | Peripheral innate and adaptive immune cells during <scp>COVID</scp>â€19: Functional neutrophils, proâ€inflammatory monocytes, and halfâ€dead lymphocytes. Cytometry Part B - Clinical Cytometry, 2022, 102, 153-167. | 0.7 | 14 |
| 378 | Single-cell landscape of peripheral immune responses to fatal SFTS. Cell Reports, 2021, 37, 110039. | 2.9 | 19 |
| 380 | Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19. Frontiers in Immunology, 2021, 12, 756262. | 2.2 | 35 |
| 382 | Co-Regulation of Protein Coding Genes by Transcription Factor and Long Non-Coding RNA in SARS-CoV-2 Infected Cells: An In Silico Analysis. Non-coding RNA, 2021, 7, 74. | 1.3 | 5 |
| 383 | Pathogenesis of Respiratory Viral and Fungal Coinfections. Clinical Microbiology Reviews, 2022, 35, e0009421. | 5.7 | 64 |
| 384 | Transcriptional Profiling and Machine Learning Unveil a Concordant Biosignature of Type I Interferon-Inducible Host Response Across Nasal Swab and Pulmonary Tissue for COVID-19 Diagnosis. Frontiers in Immunology, 2021, 12, 733171. | 2.2 | 20 |
| 385 | Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. RSC Drug Discovery Series, 2021, , 45-60. | 0.2 | 0 |
| 386 | Alveolar macrophages: novel therapeutic targets for respiratory diseases. Expert Reviews in Molecular Medicine, 2021, 23, e18. | 1.6 | 10 |
| 387 | All hands on deck: SARS-CoV-2 proteins that block early anti-viral interferon responses. Current Research in Virological Science, 2021, 2, 100015. | 1.8 | 26 |
| 388 | The cGASâ€“STING pathway drives type I IFN immunopathology in COVID-19. Nature, 2022, 603, 145-151. | 13.7 | 272 |
| 389 | Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation. Nature Communications, 2022, 13, 269. | 5.8 | 16 |
| 390 | Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598. | 13.7 | 216 |
| 391 | Beyond Good and Evil: Molecular Mechanisms of Type I and III IFN Functions. Journal of Immunology, 2022, 208, 247-256. | 0.4 | 27 |
| 392 | Myeloid cell nuclear differentiation antigen controls the pathogen-stimulated type I interferon cascade in human monocytes by transcriptional regulation of IRF7. Nature Communications, 2022, 13, 14. | 5.8 | 18 |
| 393 | Immune Profiling of COVID-19 in Correlation with SARS and MERS. Viruses, 2022, 14, 164. | 1.5 | 11 |
| 394 | A Journey into the Clinical Relevance of Heme Oxygenase 1 for Human Inflammatory Disease and Viral Clearance: Why Does It Matter on the COVID-19 Scene?. Antioxidants, 2022, 11, 276. | 2.2 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 395 | Type I interferons and SARS-CoV-2: from cells to organisms. Current Opinion in Immunology, 2022, 74, 172-182. | 2.4 | 49 |
| 396 | Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nature Communications, 2022, 13, 153. | 5.8 | 45 |
| 397 | Implications of the Immune Polymorphisms of the Host and the Genetic Variability of SARS-CoV-2 in the Development of COVID-19. Viruses, 2022, 14, 94. | 1.5 | 7 |
| 398 | Onco-immunological Aspect of COVID-19: Current Progress and Perceptions. Coronaviruses, 2022, 03, . | 0.2 | 0 |
| 400 | Avian cytokines and their receptors. , 2022, , 249-276. | | 6 |
| 401 | Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching. Cureus, 2022, 14, e21272. | 0.2 | 10 |
| 403 | Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development. Journal of Molecular Biology, 2022, 434, 167438. | 2.0 | 7 |
| 405 | Low levels of CIITA and high levels of SOCS1 predict COVID-19 disease severity in children and adults. IScience, 2022, 25, 103595. | 1.9 | 2 |
| 406 | Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches. BMB Reports, 2022, 55, 11-19. | 1.1 | 7 |
| 408 | Strategies for fighting pandemic virus infections: Integration of virology and drug delivery. Journal of Controlled Release, 2022, 343, 361-378. | 4.8 | 11 |
| 409 | Gasdermin D Inhibits Coronavirus Infection by Promoting the Noncanonical Secretion of Beta Interferon. MBio, 2022, 13, e0360021. | 1.8 | 8 |
| 410 | Cholesterol metabolism: from lipidomics to immunology. Journal of Lipid Research, 2022, 63, 100165. | 2.0 | 27 |
| 412 | Woodsmoke particle exposure prior to SARS-CoV-2 infection alters antiviral response gene expression in human nasal epithelial cells in a sex-dependent manner. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L479-L494. | 1.3 | 10 |
| 413 | Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host. International Immunopharmacology, 2022, 105, 108531. | 1.7 | 1 |
| 414 | A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease. International Journal of Molecular Sciences, 2022, 23, 1850. | 1.8 | 4 |
| 415 | Microbiota regulation of viral infections through interferon signaling. Trends in Microbiology, 2022, 30, 778-792. | 3.5 | 41 |
| 416 | Phase separation by the SARS-CoV-2 nucleocapsid protein: Consensus and open questions. Journal of Biological Chemistry, 2022, 298, 101677. | 1.6 | 44 |
| 417 | SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19. International Journal of Molecular Sciences, 2022, 23, 1716. | 1.8 | 107 |

| # | Article | IF | Citations |
|---|---|---|---|
| 418 | Nasalferon, a new nasal formulation of IFNÎ±2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood. Clinical Immunology Communications, 2022, 2, 39-45. | 0.5 | 2 |
| 419 | Neurological manifestations found in children with multisystem inflammatory syndrome. Experimental and Therapeutic Medicine, 2022, 23, 261. | 0.8 | 14 |
| 420 | SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways. Journal of Microbiology, 2022, 60, 290-299. | 1.3 | 24 |
| 421 | Myeloid cell interferon responses correlate with clearance of SARS-CoV-2. Nature Communications, 2022, 13, 679. | 5.8 | 30 |
| 422 | Specific anti-SARS-CoV-2 S1 IgY-scFv is a promising tool for recognition of the virus. AMB Express, 2022, 12, 18. | 1.4 | 10 |
| 423 | Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial. Gut, 2022, 71, 879-888. | 6.1 | 24 |
| 424 | SARS-CoV-2 infection causes intestinal cell damage: Role of interferonâ€™s imbalance. Cytokine, 2022, 152, 155826. | 1.4 | 11 |
| 425 | Modeling SARS-CoV-2 Infection in Mice Using Lentiviral hACE2 Vectors Infers Two Modes of Immune Responses to SARS-CoV-2 Infection. Viruses, 2022, 14, 11. | 1.5 | 0 |
| 426 | The mechanisms of action of ivermectin against SARS-CoV-2â€”an extensive review. Journal of Antibiotics, 2022, 75, 60-71. | 1.0 | 37 |
| 427 | SARS-CoV-2 spreads through cell-to-cell transmission. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 145 |
| 428 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) and Spike (S) Proteins Antagonize Host Type I Interferon Response. Frontiers in Cellular and Infection Microbiology, 2021, 11, 766922. | 1.8 | 26 |
| 429 | Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections. Viruses, 2021, 13, 2489. | 1.5 | 20 |
| 430 | SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-ÎºB pathway. ELife, 2021, 10, . | 2.8 | 215 |
| 431 | Profiling transcription factor sub-networks in type I interferon signaling and in response to SARS-CoV-2 infection. Computational and Mathematical Biophysics, 2021, 9, 273-288. | 0.6 | 2 |
| 432 | Cell specific peripheral immune responses predict survival in critical COVID-19 patients. Nature Communications, 2022, 13, 882. | 5.8 | 19 |
| 433 | Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19. Cytokine and Growth Factor Reviews, 2022, 63, 23-33. | 3.2 | 7 |
| 434 | Executable network of SARS-CoV-2-host interaction predicts drug combination treatments. Npj Digital Medicine, 2022, 5, 18. | 5.7 | 5 |
| 436 | Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection. Nature Communications, 2022, 13, 1018. | 5.8 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 437 | Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 18 |
| 438 | A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval. Drug Design, Development and Therapy, 2022, Volume 16, 685-715. | 2.0 | 30 |
| 439 | Uncovering Novel Viral Innate Immune Evasion Strategies: What Has SARS-CoV-2 Taught Us?. Frontiers in Microbiology, 2022, 13, 844447. | 1.5 | 4 |
| 440 | Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells. Journal of Virology, 2022, 96, e0170521. | 1.5 | 17 |
| 445 | Distinct Cellular Immune Responses to SARS-CoV-2 in Pregnant Women. Journal of Immunology, 2022, 208, 1857-1872. | 0.4 | 16 |
| 446 | Organ manifestations of COVID-19: what have we learned so far (not only) from autopsies?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 139-159. | 1.4 | 28 |
| 447 | The Impact of Onset Age on Eosinophils in Kawasaki Disease. Biomedicines, 2022, 10, 835. | 1.4 | 7 |
| 448 | Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19. Frontiers in Immunology, 2022, 13, 838132. | 2.2 | 10 |
| 449 | Mono- and combinational drug therapies for global viral pandemic preparedness. IScience, 2022, 25, 104112. | 1.9 | 19 |
| 451 | Gut Microbiota might act as a potential therapeutic pathway in COVID-19. Current Pharmaceutical Biotechnology, 2022, 23, . | 0.9 | 1 |
| 452 | Cellular, Antibody and Cytokine Pathways in Children with Acute SARS-CoV-2 Infection and MIS-Câ€"Can We Match the Puzzle?. Antibodies, 2022, 11, 25. | 1.2 | 11 |
| 453 | The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-Î³ release by natural killer cells. Vaccine, 2022, 40, 2619-2625. | 1.7 | 6 |
| 454 | Human enteric viruses autonomously shape inflammatory bowel disease phenotype through divergent innate immunomodulation. Science Immunology, 2022, 7, eabn6660. | 5.6 | 38 |
| 455 | Risk factors, immune response and wholeâ€genome sequencing of SARSâ€CoVâ€2 in a cruise ship outbreak in Norway. International Journal of Infectious Diseases, 2022, 118, 10-20. | 1.5 | 6 |
| 456 | A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells. Journal of Immunological Methods, 2022, 504, 113263. | 0.6 | 4 |
| 457 | Detection of A-to-I RNA Editing in SARS-COV-2. Genes, 2022, 13, 41. | 1.0 | 24 |
| 458 | SARS-CoV-2-Encoded MiRNAs Inhibit Host Type I Interferon Pathway and Mediate Allelic Differential Expression of Susceptible Gene. Frontiers in Immunology, 2021, 12, 767726. | 2.2 | 17 |
| 459 | Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19: A Retrospective Cohort Study. Frontiers in Immunology, 2021, 12, 791348. | 2.2 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 460 | Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. Genes and Immunity, 2022, 23, 51-56. | 2.2 | 41 |
| 461 | An update on host immunity correlates and prospects of re-infection in COVID-19. International Reviews of Immunology, 2022, 41, 367-392. | 1.5 | 9 |
| 462 | Why Does the Severity of COVID-19 Differ With Age?. Pediatric Infectious Disease Journal, 2022, 41, e36-e45. | 1.1 | 49 |
| 466 | SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers. International Journal of Hematology-Oncology and Stem Cell Research, 0, , . | 0.3 | 4 |
| 467 | Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor. PLoS Pathogens, 2022, 18, e1010464. | 2.1 | 24 |
| 468 | Nasally delivered interferon-Î» protects mice against infection by SARS-CoV-2 variants including Omicron. Cell Reports, 2022, 39, 110799. | 2.9 | 39 |
| 470 | Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis. International Journal of Molecular Sciences, 2022, 23, 4268. | 1.8 | 10 |
| 471 | Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction. Vaccines, 2022, 10, 614. | 2.1 | 10 |
| 472 | SARS-CoV-2 spike proteinâ€“induced cell fusion activates the cGAS-STING pathway and the interferon response. Science Signaling, 2022, 15, eabg8744. | 1.6 | 54 |
| 485 | SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. Inflammation, 2022, 45, 1430-1449. | 1.7 | 16 |
| 486 | Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches.. BMB Reports, 2021, , . | 1.1 | 0 |
| 488 | Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities. Journal of Clinical Medicine, 2022, 11, 2422. | 1.0 | 0 |
| 489 | Immunouniverse of SARS-CoV-2. Immunological Medicine, 2022, 45, 186-224. | 1.4 | 8 |
| 491 | HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19. Frontiers in Immunology, 2022, 13, 841716. | 2.2 | 15 |
| 494 | Airway epithelial interferon response to SARS-CoV-2 is inferior to rhinovirus and heterologous rhinovirus infection suppresses SARS-CoV-2 replication. Scientific Reports, 2022, 12, 6972. | 1.6 | 12 |
| 495 | Infectious Bronchitis Virus Nsp14 Degrades JAK1 to Inhibit the JAK-STAT Signaling Pathway in HD11 Cells. Viruses, 2022, 14, 1045. | 1.5 | 7 |
| 496 | SARS-CoV-2: overview of immune response, insights into vaccine platforms and their challenges. Exploration of Immunology, 0, , 245-263. | 1.7 | 0 |
| 497 | How SARS-CoV-2 dodges immune surveillance and facilitates infection: an analytical review. Expert Review of Anti-Infective Therapy, 2022, 20, 1119-1127. | 2.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 498 | Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. Frontiers in Immunology, 2022, 13, . | 2.2 | 29 |
| 501 | Gene Set Enrichment Analysis Reveals That Fucoidan Induces Type I IFN Pathways in BMDC. Nutrients, 2022, 14, 2242. | 1.7 | 5 |
| 503 | COVID-19 and its impact on cancer, HIV, and mentally ill patients. , 2022, , 95-137. | | 1 |
| 504 | Body temperature variation controls pre-mRNA processing and transcription of antiviral genes and SARS-CoV-2 replication. Nucleic Acids Research, 2022, 50, 6769-6785. | 6.5 | 6 |
| 505 | Immune system changes in those with hypertension when infected with SARS-CoV-2. Cellular Immunology, 2022, 378, 104562. | 1.4 | 2 |
| 506 | Potential therapeutic effects of Ivermectin in COVID-19. Experimental Biology and Medicine, 2022, 247, 1388-1396. | 1.1 | 2 |
| 507 | Individual and Synergistic Anti-Coronavirus Activities of SOCS1/3 Antagonist and Interferon Î±1 Peptides. Frontiers in Immunology, 0, 13, . | 2.2 | 6 |
| 508 | Conjunctival epithelial cells resist productive SARS-CoV-2 infection. Stem Cell Reports, 2022, 17, 1699-1713. | 2.3 | 5 |
| 509 | Cytokines and microRNAs in SARS-CoV-2: What do we know?. Molecular Therapy - Nucleic Acids, 2022, 29, 219-242. | 2.3 | 18 |
| 510 | Host-directed immunotherapy of viral and bacterial infections: past, present and future. Nature Reviews Immunology, 2023, 23, 121-133. | 10.6 | 71 |
| 511 | A diminished immune response underlies age-related SARS-CoV-2 pathologies. Cell Reports, 2022, 39, 111002. | 2.9 | 20 |
| 512 | In silico drug repurposing against SARS-CoV-2 using an integrative transcriptomic profiling approach: Hydrocortisone and Benzhydrocodone as potential drug candidates against COVID-19. Infection, Genetics and Evolution, 2022, 103, 105318. | 1.0 | 3 |
| 513 | Lungsâ€"Inflammatory and respiratory system. , 2022, , 231-242. | | 0 |
| 514 | Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019. Frontiers in Microbiology, 0, 13, . | 1.5 | 18 |
| 515 | Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms. PLoS Pathogens, 2022, 18, e1010630. | 2.1 | 14 |
| 517 | Genetic polymorphisms in TLR3, IL10 and CD209 influence the risk of BK polyomavirus infection after kidney transplantation. Scientific Reports, 2022, 12, . | 1.6 | 4 |
| 518 | Additional Evidence for Commonalities between COVID-19 and Radiation Injury: Novel Insight into COVID-19 Candidate Drugs. Radiation Research, 2022, 198, . | 0.7 | 4 |
| 520 | Advancing Lung Immunology Research: An Official American Thoracic Society Workshop Report. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, e1-18. | 1.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 521 | Dengue and COVID-19: two sides of the same coin. Journal of Biomedical Science, 2022, 29, . | 2.6 | 16 |
| 522 | Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion. Scientific Reports, 2022, 12, . | 1.6 | 8 |
| 523 | Overview of the immunological mechanism underlying severe fever with thrombocytopenia syndrome (Review). International Journal of Molecular Medicine, 2022, 50, . | 1.8 | 11 |
| 524 | A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients. Cell Communication and Signaling, 2022, 20, . | 2.7 | 19 |
| 525 | Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1336-1352. | 2.5 | 28 |
| 526 | Understanding the epigenetic mechanisms in SARS CoV-2 infection and potential therapeutic approaches. Virus Research, 2022, 318, 198853. | 1.1 | 11 |
| 527 | Porcine epidemic diarrhea virus strain FJzz1 infection induces type I/III IFNs production through RLRs and TLRs-mediated signaling. Frontiers in Immunology, 0, 13, . | 2.2 | 0 |
| 528 | Bioinformatics analysis of potential common pathogenic mechanisms for COVID-19 infection and primary Sjogrenâ€™s syndrome. Frontiers in Immunology, 0, 13, . | 2.2 | 8 |
| 529 | Deactylation by SIRT1 enables liquidâ€“liquid phase separation of IRF3/IRF7 in innate antiviral immunity. Nature Immunology, 2022, 23, 1193-1207. | 7.0 | 22 |
| 530 | Melatonin: Regulation of Viral Phase Separation and Epitranscriptomics in Post-Acute Sequelae of COVID-19. International Journal of Molecular Sciences, 2022, 23, 8122. | 1.8 | 7 |
| 531 | Inflammatory pathways in COVIDâ€19: Mechanism and therapeutic interventions. MedComm, 2022, 3, . | 3.1 | 17 |
| 532 | Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. Genome Medicine, 2022, 14, . | 3.6 | 28 |
| 533 | Human coronaviruses disassemble processing bodies. PLoS Pathogens, 2022, 18, e1010724. | 2.1 | 9 |
| 534 | Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection. Biomedical Journal, 2022, , . | 1.4 | 3 |
| 535 | Self-assembling short immunostimulatory duplex RNAs with broad-spectrum antiviral activity. Molecular Therapy - Nucleic Acids, 2022, 29, 923-940. | 2.3 | 7 |
| 536 | Impaired activation of transposable elements in <scp>SARSâ€CoV</scp>â€2 infection. EMBO Reports, 2022, 23, . | 2.0 | 9 |
| 538 | USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING. Cell Death and Disease, 2022, 13, . | 2.7 | 9 |
| 539 | Roles and functions of SARS-CoV-2 proteins in host immune evasion. Frontiers in Immunology, 0, 13, . | 2.2 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 540 | Review of human interferons and the potential of their use in the complex therapy of a new coronavirus infection COVID-19. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 38-44. | 0.2 | 0 |
| 541 | Importancia de los Interferones en la respuesta inmune antiviral contra SARS-CoV-2. Revista De La Universidad Industrial De Santander Salud, 2022, 54, . | 0.0 | 0 |
| 542 | Respiratory and systemic monocytes, dendritic cells, and myeloidâ€derived suppressor cells in COVIDâ€19: Implications for disease severity. Journal of Internal Medicine, 2023, 293, 130-143. | 2.7 | 16 |
| 543 | Interferon Î±-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 544 | Initial activation of STAT2 induced by IAV infection is critical for innate antiviral immunity. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 545 | SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion. Viruses, 2022, 14, 1991. | 1.5 | 19 |
| 546 | More tools for our toolkit: The application of HEL-299 cells and dsRNA-nanoparticles to study human coronaviruses in vitro. Virus Research, 2022, 321, 198925. | 1.1 | 4 |
| 547 | SARS-CoV-2 and the Nucleus. International Journal of Biological Sciences, 2022, 18, 4731-4743. | 2.6 | 11 |
| 548 | COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. Frontiers in Medicine, 0, 9, . | 1.2 | 4 |
| 549 | Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects. Cureus, 2022, , . | 0.2 | 2 |
| 550 | Distinct Molecular Mechanisms Characterizing Pathogenesis of SARS-CoV-2. Journal of Microbiology and Biotechnology, 2022, 32, 1073-1085. | 0.9 | 2 |
| 551 | Potential Therapeutic Role of Mesenchymal-Derived Stem Cells as an Alternative Therapy to Combat COVID-19 through Cytokines Storm. Cells, 2022, 11, 2686. | 1.8 | 1 |
| 552 | The multifaceted roles of NLRP3-modulating proteins in virus infection. Frontiers in Immunology, 0, 13, . | 2.2 | 10 |
| 553 | Identification of methylation signatures and rules for predicting the severity of SARS-CoV-2 infection with machine learning methods. Frontiers in Microbiology, 0, 13, . | 1.5 | 2 |
| 555 | COVID-19 vs. Cancer Immunosurveillance: A Game of Thrones within an Inflamed Microenviroment. Cancers, 2022, 14, 4330. | 1.7 | 4 |
| 556 | Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic. Frontiers in Immunology, 0, 13, . | 2.2 | 2 |
| 557 | Impaired immune response drives age-dependent severity of COVID-19. Journal of Experimental Medicine, 2022, 219, . | 4.2 | 26 |
| 558 | Regulation of cGAS Activity and Downstream Signaling. Cells, 2022, 11, 2812. | 1.8 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 559 | Nineteen months into the pandemic, what have we learned about <scp>COVID</scp>â€19â€related outcomes in patients with psoriasis?. Journal of Cosmetic Dermatology, 2022, 21, 6549-6553. | 0.8 | 2 |
| 560 | Efficacy of Lactococcus lactis strain plasma (LC-Plasma) in easing symptoms in patients with mild COVID-19: protocol for an exploratory, multicentre, double-blinded, randomised controlled trial (PLATEAU study). BMJ Open, 2022, 12, e061172. | 0.8 | 1 |
| 561 | Quantitative proteomic analysis of SARS-CoV-2 infection of primary human airway ciliated cells and lung epithelial cells demonstrates the effectiveness of SARS-CoV-2 innate immune evasion. Wellcome Open Research, 0, 7, 224. | 0.9 | 2 |
| 562 | COVID-19: imbalanced cell-mediated immune response drives to immunopathology. Emerging Microbes and Infections, 2022, 11, 2393-2404. | 3.0 | 9 |
| 563 | Correlation between Type I Interferon Associated Factors and COVID-19 Severity. International Journal of Molecular Sciences, 2022, 23, 10968. | 1.8 | 9 |
| 564 | COVIDâ€19 immunopathology: From acute diseases to chronic sequelae. Journal of Medical Virology, 2023, 95, . | 2.5 | 24 |
| 565 | Antiviral activity of mink interferon alpha expressed in the yeast Pichia pastoris. Frontiers in Veterinary Science, 0, 9, . | 0.9 | 0 |
| 566 | SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant. Frontiers in Immunology, 0, 13, . | 2.2 | 7 |
| 567 | IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA. Frontiers in Immunology, 0, 13, . | 2.2 | 12 |
| 569 | Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz. Iranian Journal of Science and Technology, Transaction A: Science, 0, , . | 0.7 | 0 |
| 570 | Inflammasome Genetic Variants Are Associated with Protection to Clinical Severity of COVID-19 among Patients from Rio de Janeiro, Brazil. BioMed Research International, 2022, 2022, 1-15. | 0.9 | 3 |
| 571 | Cytokine storm-calming property of the isoquinoline alkaloids in Coptis chinensis Franch. Frontiers in Pharmacology, 0, 13, . | 1.6 | 6 |
| 572 | Molecular insights into onset of autoimmunity in SARSâ€CoVâ€2 infected patients. Rheumatology & Autoimmunity, 2022, 2, 198-202. | 0.3 | 4 |
| 575 | Discovering Common Pathogenic Mechanisms of COVID-19 and Parkinson Disease: An Integrated Bioinformatics Analysis. Journal of Molecular Neuroscience, 2022, 72, 2326-2337. | 1.1 | 4 |
| 576 | Restoration of dendritic cell homeostasis and Type I/Type III interferon levels in convalescent COVID-19 individuals. BMC Immunology, 2022, 23, . | 0.9 | 6 |
| 577 | CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. PLoS Pathogens, 2022, 18, e1010479. | 2.1 | 15 |
| 578 | Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome. Immunity, 2022, 55, 2074-2084.e5. | 6.6 | 15 |
| 579 | Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study. ELife, 0, 11, . | 2.8 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 580 | Inosine: A broad-spectrum anti-inflammatory against SARS-CoV-2 infection-induced acute lung injury via suppressing TBK1 phosphorylation. Journal of Pharmaceutical Analysis, 2023, 13, 11-23. | 2.4 | 3 |
| 581 | Pseudorabies virus-induced expression and antiviral activity of type I or type III interferon depend on the type of infected epithelial cell. Frontiers in Immunology, 0, 13, . | 2.2 | 1 |
| 582 | A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. Life, 2022, 12, 1758. | 1.1 | 9 |
| 583 | Leukocyte metabolism in obese type 2 diabetic individuals associated with COVID-19 severity. Frontiers in Microbiology, 0, 13, . | 1.5 | 1 |
| 584 | COVID-DSNet: A novel deep convolutional neural network for detection of coronavirus (SARS-CoV-2) cases from CT and Chest X-Ray images. Artificial Intelligence in Medicine, 2022, 134, 102427. | 3.8 | 16 |
| 585 | II. COVID-19: How Far Has the Pathogenesis been Elucidated?. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2355-2360. | 0.0 | 0 |
| 586 | A persistent neutrophil-associated immune signature characterizes postâ€“COVID-19 pulmonary sequelae. Science Translational Medicine, 2022, 14, . | 5.8 | 43 |
| 587 | Gut microbiome and anti-viral immunity in COVID-19. Critical Reviews in Food Science and Nutrition, 0, , 1-16. | 5.4 | 5 |
| 588 | Immune-profiling of SARS-CoV-2 viremic patients reveals dysregulated innate immune responses. Frontiers in Immunology, 0, 13, . | 2.2 | 1 |
| 589 | Severe Coronavirus disease (COVID)-19: from pathogenesis to therapy. Shock, 0, Publish Ahead of Print, . | 1.0 | 0 |
| 590 | SARSâ€CoVâ€2 modulation of RIGâ€Iâ€MAVS signaling: Potential mechanisms of impairment on host antiviral immunity and therapeutic approaches. , 2022, 1, . | | 3 |
| 591 | Immune phenotypes that are associated with subsequent COVID-19 severity inferred from post-recovery samples. Nature Communications, 2022, 13, . | 5.8 | 12 |
| 592 | Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. Journal of Translational Medicine, 2022, 20, . | 1.8 | 29 |
| 593 | Molecular Function of cGAS-STING in SARS-CoV-2: A Novel Approach to COVID-19 Treatment. BioMed Research International, 2022, 2022, 1-10. | 0.9 | 3 |
| 594 | Integrative transcriptome analysis of SARS-CoV-2 human-infected cells combined with deep learning algorithms identifies two potential cellular targets for the treatment of coronavirus disease. Brazilian Journal of Microbiology, 0, , . | 0.8 | 1 |
| 595 | Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors. Journal of Translational Medicine, 2022, 20, . | 1.8 | 6 |
| 596 | Potential role of <scp>AIM2</scp> inflammasome in <scp>SARSâ€CoV</scp>â€2 infection. Scandinavian Journal of Immunology, 2023, 97, . | 1.3 | 2 |
| 597 | Guanylate-binding protein 1 restricts avian coronavirus infectious bronchitis virus-infected HD11 cells. Poultry Science, 2023, 102, 102398. | 1.5 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 598 | Differential peripheral blood mononuclear cell reactivity against SARS-CoV-2 proteins in naÃ¯ve and previously infected subjects following COVID-19 vaccination. Clinical Immunology Communications, 2022, 2, 172-176. | 0.5 | 3 |
| 600 | Cellular APOBEC3A deaminase drives mutations in the SARS-CoV-2 genome. Nucleic Acids Research, 2023, 51, 783-795. | 6.5 | 21 |
| 602 | Transiently heritable fates and quorum sensing drive early IFN-I response dynamics. ELife, 0, 12, . | 2.8 | 5 |
| 603 | The race to understand immunopathology in COVID-19: Perspectives on the impact of quantitative approaches to understand within-host interactions. ImmunoInformatics, 2023, 9, 100021. | 1.2 | 1 |
| 604 | Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. Biology, 2023, 12, 177. | 1.3 | 11 |
| 605 | Dynamic activity in cis-regulatory elements of leukocytes identifies transcription factor activation and stratifies COVID-19 severity in ICU patients. Cell Reports Medicine, 2023, 4, 100935. | 3.3 | 2 |
| 606 | Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. Trends in Molecular Medicine, 2023, 29, 255-267. | 3.5 | 17 |
| 607 | Immunologic Interplay Between HIV/AIDS and COVID-19: Adding Fuel to the Flames?. Current HIV/AIDS Reports, 2023, 20, 51-75. | 1.1 | 9 |
| 608 | Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis. Frontiers in Immunology, 0, 14, . | 2.2 | 10 |
| 610 | Isolation and characterization of the mink interferon-epsilon gene and its antiviral activity. Frontiers in Veterinary Science, 0, 9, . | 0.9 | 0 |
| 611 | Cutaneous manifestations in elderly patients with confirmed coronavirus disease 2019 and the disease outcomes: A systematic review. Journal of Dermatology, 2023, 50, 679-691. | 0.6 | 0 |
| 612 | Type I and III interferons are good markers to monitor COVID-19 pathophysiology. Cytokine, 2023, 165, 156172. | 1.4 | 3 |
| 614 | Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2. Nature Communications, 2023, 14, . | 5.8 | 16 |
| 616 | SARSâ€CoVâ€2 NSP7 inhibits type I and III IFN production by targeting the RIGâ€I/MDA5, TRIF, and STING signaling pathways. Journal of Medical Virology, 2023, 95, . | 2.5 | 14 |
| 617 | ADP-Ribosylation in Antiviral Innate Immune Response. Pathogens, 2023, 12, 303. | 1.2 | 2 |
| 618 | Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV. Vaccines, 2023, 11, 480. | 2.1 | 0 |
| 619 | Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19. Acta Pharmaceutica Sinica B, 2023, 13, 3638-3658. | 5.7 | 2 |
| 620 | Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial. Frontiers in Medicine, 0, 10, . | 1.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 621 | Structural-based design of HD-TAC7 PROteolysis TArgeting chimeras (PROTACs) candidate transformations to abrogate SARS-CoV-2 infection. Journal of Biomolecular Structure and Dynamics, 2023, 41, 14566-14581. | 2.0 | 2 |
| 622 | COVID-19 Biogenesis and Intracellular Transport. International Journal of Molecular Sciences, 2023, 24, 4523. | 1.8 | 7 |
| 623 | Treating COVID-19: Targeting the Host Response, Not the Virus. Life, 2023, 13, 712. | 1.1 | 2 |
| 625 | New insights for infection mechanism and potential targets of COVID-19: Three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches. Chinese Herbal Medicines, 2023, 15, 157-168. | 1.2 | 3 |
| 626 | Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines. Vaccines, 2023, 11, 615. | 2.1 | 2 |
| 629 | Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19. Frontiers in Immunology, 0, 14, . | 2.2 | 4 |
| 630 | Prospective Roles of Tumor Necrosis Factor-Alpha (TNF-Î±) in COVID-19: Prognosis, Therapeutic and Management. International Journal of Molecular Sciences, 2023, 24, 6142. | 1.8 | 17 |
| 631 | Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients. Frontiers in Immunology, 0, 14, . | 2.2 | 1 |
| 632 | Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+Î²7 integrin+ T cells and anti-SARS-CoV-2 IgA response. Nature Communications, 2023, 14, . | 5.8 | 12 |
| 633 | The Role of Cytokines in Cholesterol Accumulation in Cells and Atherosclerosis Progression. International Journal of Molecular Sciences, 2023, 24, 6426. | 1.8 | 5 |
| 634 | Interferon-lambda: New functions on intestinal symptoms in COVID-19. World Journal of Gastroenterology, 0, 29, 1942-1954. | 1.4 | 2 |
| 635 | Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseasesâ€"Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway. International Journal of Molecular Sciences, 2023, 24, 6736. | 1.8 | 1 |
| 636 | Therapeutic Effectiveness of Interferon-Î±2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience. International Journal of Molecular Sciences, 2023, 24, 6887. | 1.8 | 4 |
| 637 | Analysis of the Differential Expression and Antiviral Activity of Porcine Interferon-Î± In Vitro. International Journal of Peptide Research and Therapeutics, 2023, 29, . | 0.9 | 1 |
| 638 | SARS-CoV-2 infection aggravates cigarette smoke-exposed cell damage in primary human airway epithelia. Virology Journal, 2023, 20, . | 1.4 | 4 |
| 639 | Cytoplasmic DNAs: Sources, sensing, and roles in the development of lung inflammatory diseases and cancer. Frontiers in Immunology, 0, 14, . | 2.2 | 1 |
| 640 | Potential of Interleukin (IL)-12 Group as Antivirals: Severe Viral Disease Prevention and Management. International Journal of Molecular Sciences, 2023, 24, 7350. | 1.8 | 3 |
| 641 | Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection. Frontiers in Immunology, 0, 14, . | 2.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 642 | Plasmacytoid dendritic cells stimulated with Lactococcus lactis strain Plasma produce soluble factors to suppress SARS-CoV-2 replication. Biochemical and Biophysical Research Communications, 2023, 662, 26-30. | 1.0 | 1 |
| 664 | Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review. Neurology and Therapy, 0, , . | 1.4 | 1 |
| 703 | The Potential of Bacteriophages in Treating Covid-19-Associated Secondary Infections. , 2023, , 547-579. | | 0 |
| 710 | CHITV: an updated combination treatment regimen for COVID-19. , 2024, , 2743-2751. | | 0 |